Bioasis Technologies Competitors

Covalon Technologies (CVE:COV) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Valuation & Earnings

This table compares Covalon Technologies and Bioasis Technologies' gross revenue, earnings per share (EPS) and valuation.

Bioasis Technologies has lower revenue, but higher earnings than Covalon Technologies. Covalon Technologies is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Covalon Technologies and Bioasis Technologies' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Covalon Technologies and Bioasis Technologies, as provided by MarketBeat.com.

Summary

Bioasis Technologies beats Covalon Technologies on 4 of the 5 factors compared between the two stocks.

Emerald Health Therapeutics (CVE:EMH) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Emerald Health Therapeutics and Bioasis Technologies, as reported by MarketBeat.com.

Profitability

This table compares Emerald Health Therapeutics and Bioasis Technologies' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Emerald Health Therapeutics and Bioasis Technologies' gross revenue, earnings per share and valuation.

Bioasis Technologies has lower revenue, but higher earnings than Emerald Health Therapeutics. Emerald Health Therapeutics is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Bioasis Technologies beats Emerald Health Therapeutics on 4 of the 5 factors compared between the two stocks.

Bioasis Technologies (CVE:BTI) and IntelGenx Technologies (CVE:IGX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Valuation and Earnings

This table compares Bioasis Technologies and IntelGenx Technologies' revenue, earnings per share and valuation.

Bioasis Technologies has higher revenue and earnings than IntelGenx Technologies. IntelGenx Technologies is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Bioasis Technologies and IntelGenx Technologies, as provided by MarketBeat.

Profitability

This table compares Bioasis Technologies and IntelGenx Technologies' net margins, return on equity and return on assets.

Summary

Bioasis Technologies beats IntelGenx Technologies on 4 of the 5 factors compared between the two stocks.

Bioasis Technologies (CVE:BTI) and Quest PharmaTech (CVE:QPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings for Bioasis Technologies and Quest PharmaTech, as provided by MarketBeat.com.

Profitability

This table compares Bioasis Technologies and Quest PharmaTech's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Bioasis Technologies and Quest PharmaTech's revenue, earnings per share (EPS) and valuation.

Quest PharmaTech has lower revenue, but higher earnings than Bioasis Technologies. Quest PharmaTech is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Quest PharmaTech beats Bioasis Technologies on 3 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Profitability

This table compares Ceapro and Bioasis Technologies' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Ceapro and Bioasis Technologies, as provided by MarketBeat.

Earnings & Valuation

This table compares Ceapro and Bioasis Technologies' gross revenue, earnings per share (EPS) and valuation.

Ceapro has higher revenue and earnings than Bioasis Technologies. Ceapro is trading at a lower price-to-earnings ratio than Bioasis Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Bioasis Technologies on 3 of the 5 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Bioasis Technologies (CVE:BTI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Profitability

This table compares Crescita Therapeutics and Bioasis Technologies' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Crescita Therapeutics and Bioasis Technologies' top-line revenue, earnings per share and valuation.

Bioasis Technologies has lower revenue, but higher earnings than Crescita Therapeutics. Bioasis Technologies is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Crescita Therapeutics and Bioasis Technologies, as provided by MarketBeat.

Summary

Bioasis Technologies beats Crescita Therapeutics on 3 of the 5 factors compared between the two stocks.